AADI
Aadi Bioscience, Inc.·Healthcare
2.05
2.381%(−0.05)
Market ClosedLast Updated: — ET
52W L: $1.2152W H: $3.81
AADI NEWS
defenseworld.net
Mar 28
Aadi Bioscience (NASDAQ:AADI) and Ayala Pharmaceuticals (NASDAQ:ADXS) Head to Head Analysis
Insider and Institutional Ownership 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money
defenseworld.net
Mar 12
Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027
Whitehawk Therapeutics CEO Dave Lennon outlined the company's strategy and near-term milestones at the Inaugural Life Sciences Conference in Miami, describing a three-program antibody-drug conjugate (ADC) pipeline built around a shared linker-payload system and focused on targets the company believes can support broad activity across multiple tumor types. Company reset and runway Lennon said the
defenseworld.net
Mar 5
Aadi Bioscience Conference: Whitehawk CEO Details 3-Program ADC Pipeline, First Data Seen in 2027
Whitehawk Therapeutics CEO Dave Lennon presented at TD Cowen's 46th Annual Healthcare Conference, outlining the company's strategy to develop a portfolio of next-generation antibody-drug conjugates (ADCs) and discussing early priorities for its first-in-human studies. Lennon said Whitehawk has advanced two ADC programs into the clinic since launching last year and is working toward initiating a
defenseworld.net
Jan 28
Aadi Bioscience (NASDAQ:AADI) versus Nabriva Therapeutics (NASDAQ:NBRV) Head-To-Head Analysis
Profitability This table compares Aadi Bioscience and Nabriva Therapeutics' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Aadi Bioscience -246.06% -71.87% -57.28% Nabriva Therapeutics -148.11% -365.53% -135.81% Institutional and Insider Ownership 52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics
defenseworld.net
Jan 22
Reviewing Actinium Pharmaceuticals (NYSE:ATNM) & Aadi Bioscience (NASDAQ:AADI)
Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Aadi Bioscience (NASDAQ: AADI - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings. Volatility and Risk Actinium Pharmaceuticals has a
